INNOVATION
PATIENT-CENTRED
INTEGRITY
COLLABORATION
About us
FoxBio Therapeutics is a next-generation biotech company pioneering in CAR-Treg therapy using regulatory T cells (Treg) engineered with a chimeric antigen receptor (CAR) to revolutionize the treatment of autoimmune and inflammatory diseases.
By restoring immune balance and delivering lasting remission, we address the urgent unmet needs of over 500 million patients worldwide, transforming lives where conventional therapies fall short.
Our mission
At FoxBio, our mission is to redefine the treatment of chronic inflammatory diseases by developing curative CAR-Treg therapies that go beyond symptom management.
We aim to restore immune tolerance, offering patients lasting remission and a return to a life free from the burden of lifelong treatments.
We are pionneers
FoxBio, a trailblazing biotech company, is combining precision, safety, and long-term efficacy to deliver life-changing outcomes for patients worldwide.
Scientific and technological expertise
- Founded by leaders in Treg biology and gene & cell therapy, with more than two decades of experience
- A team with proven, deep expertise in CAR-Treg development
- Manage end-to-end cell therapy know-how: from discovery to clinical application, spanning immunology, genetic engineering, GMP manufacturing, industrialization, and clinical development
Revolutionary therapeutic approach
Our cutting-edge approach harnesses the power of regulatory T cells to restore immune balance by leading the next generation of CAR-Treg therapies, offering a breakthrough alternative to conventional treatment.
Built on Nobel – Winning science
The 2025 Nobel Prize in Physiology or Medicine recognized the discovery of Tregs and the FOXP3 gene, major advances that reshaped the field of immune regulation and strongly influence our vision today.
Our technology
FoxBio’s technology leverages engineered Tregs (CAR-Tregs), the body’s natural “peacekeepers,” enhanced with Chimeric Antigen Receptors (CARs) to precisely target and suppress pathological inflammation.
Unlike conventional therapies, our approach promotes durable immune balance and tissue repair after a single administration, setting a new standard for personalized, regenerative medicine.
Our Team
FoxBio leadership team and board members aims to transform the treatment landscape for Immune-mediated inflammatory diseases. Their deep expertise in all aspects of cell therapy, from bench to bedside, positions them at the forefront of innovation and leadership in the field of engineered Tregs.
OUR LEADERSIP TEAM
Dr. Sophie Blondel
PharmD
PhD
CEO & CO-Founder
Dr. Julie Gertner-Dardenne
PhD
CDO & Co-founder
Dr. Pierre
Pellier
MD
CMO
Virginie
Favre
MSc
CTO
Dr. Philippe Kieffer-Kwon
PhD
R&D advisor
OUR BOARD TEAM
Dr. Mathieu Allez
MD, PhD
France
Dr Sylvio Danese
MD, PhD
Italy
Dr. Iris Dotan MD,
PhD
Israel
Pr. Christian Jorgensen
MD, PhD
France
Dr Makoto Miyara
MD, PhD
France
Dr.
David Rubin
MD, PhD
USA
Our latest press release
Biotech Finance
FOXBIO, THE PHOENIX OF THE CAR-TREG In the wake of the 2025 Nobel Prize in Medicine, FoxBio is accelerating the clinical translation of CAR-Tregs to treat severe and debilitating chronic inflammatory diseases.
Grasse Biotech
Following the approval committee meeting held on December 8th, FoxBio and Grasse Biotech officially announced the integration of FoxBio into the scientific business incubator, in the heart of the Grasse region.
Contact us
